Status:
UNKNOWN
CLearing Alzheimer's Disease Molecular Pathology Without Medications
Lead Sponsor:
University Hospital, Geneva
Conditions:
Alzheimer Disease
Amyloid Plaque
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
According to the most popular pathophysiological models of Alzheimer's disease, the amyloid hypothesis, amyloid deposition is the causative event triggering a chain of other downstream events which fi...
Eligibility Criteria
Inclusion
- Informed Consent as documented by signature (Appendix Informed Consent Form),
- age 40-80,
- ≥5 years of education,
- previous evidence of brain amyloidosis (assessed by PET, CSF, or blood-based biomarkers).
Exclusion
- history of epilepsy;
- clinically relevant visual or auditory diseases/deficits;
- clinical diagnosis of dementia;
- contraindication to amyloid-PET;
- inability to undergo the procedures of the study, e.g. severe behavioral disturbances;
- severe diseases:
- Malignant neoplasm within 5 years,
- Life threatening diseases,
- Severe systemic diseases (e.g. kidney insufficiency, cardiac insufficiency, decompensated diabetes, decompensated metabolic diseases, decompensated hypothyroidism, uncontrolled autoimmune diseases);
- the participation to a clinical trial involving potential Alzheimer's disease modifying therapies;
- documented pregnancy or intention to become pregnant during the course of the study or breast feeding.
Key Trial Info
Start Date :
August 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04913454
Start Date
August 1 2021
End Date
July 31 2022
Last Update
June 4 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.